Background: The objective of our study was to evaluate the efficacy and toxicity of a high-dose melphalan-based (HDMel) therapy with or without total body irradiation (TBI) followed by peripheral blood progenitor (PBPC) transplantation in patients with multiple myeloma (MM).
Introduction
Multiple myeloma (MM) is a B-cell disorder with a median survival of three years using conventional chemotherapy [1] . Most randomized trials have failed to show an improvement in survival by using combination chemotherapy instead of melphalan with or without prednison [2, 3] . A promising treatment approach for multiple myeloma is based on reports of high complete remission rates after the administration of dose-escalated alleviating agents which was piloted by T.J. McElwain in the early 1980s using HD-Mel [4] . Hematopoietic progenitor cell transplantation allows a further increase in the dose of cytotoxic drugs and the addition of total body irradiation (TBI). The randomized IFM 90 study showed a siginificantly longer event-free survival (EFS) and overall survival (OS) in patients treated with HDMel and TBI followed by autologous bone marrow transplantation [5] . We present our single center experience of 100 patients with multiple myeloma who were included in a high-dose treatment program with PBPC transplantation.
Patients and methods

Patient characteristics
From June 1992 to May 1996, 100 patients with multiple myeloma were enrolled into this study. Inclusion criteria were: 1) MM defined as stage III according to the Durie-Salmon classification [6] or progressive stage II disease, (2) age < 65 years, (3) creatinine clearance > 60 ml/ min, (4) normal electrocardiogram (ECG), stress ECG and echocardiogram, (5) no cardiac arrhythmias > LOWN IV B in the Holter-ECG and (6) normal liver function [Serum bilirubin < 2.0 g/dl, ALAT and ASAT < 3 x normal value] and no disease progression during conventional polychemotherapy. The 100 patients analyzed in this evaluation were recruited from 127 MM patients eligible for high-dose treatment admitted at our centre between June 1992 and May 1996. Excluded from PBPC transplantation were patients with insufficient CD34+ cell harvest in at least two mobilization therapies (n = 10), a progressive disease during conventional treatment (n -15) and contraindications for PBPC transplantation (n = 1). One patient with sufficient PBPC harvest in first partial remission will be transplanted after progression at his own request. In the group of transplanted patients, 67 patients were male and 33 patients female with a median age of 51 years (range 30-65). Patient characteristics are shown in Table 1 . At our centre, patients were treated for initial tumor reduction with VAD (vincristin, Adriamycine*, dexamethasone) or VBMCP (M2-protocol, vincristin, BCNU*, melphalan, cyclophosphamide, prednisone) until the paraprotein level reached a plateau or complete remission was achieved. Patients admitted from other hospitals had been pretreated with melphalan/ prednisone (n = 40) or other chemotherapies (n = 4). To improve the remission status, 35 of these 44 patients received at least three cycles VAD. The median number of previous chemotherapy cycles was 7 (range 3-28) and 42 out of the 100 patients had a history of previous irradiation. Most patients had advanced disease (76 patients with stage III), 3 patients with symptoms of the disease were in stage I and included at their own request.
Complete and partial remission were defined according to the EBMT criteria [7] . For PR, a 50% reduction of the M-component in serum or 75% reduction of urine paraprotein were required. CR demanded normal serum protein elektrophoresis or proteinuria < 0 25 g/1 and less than 5% plasma cells in the bone marrow, but a negative immunofixation was not necessary.
PBPC mobilization
To mobilize PBPC and to reduce the tumor load before melphalancontaining high-dose therapy, 88 patients received high-dose cyclophosphamide (HD-CY, 14 patients with 4 g/m 2 , 74 patients with 7 g/m 2 CY) or in case of preexisting heart disease or amyloidosis lfosfamide/ mitoxantrone (12 patients). Twenty-four-hour post-chemotherapy, Filgrastim (R-metHuG-CSF, 300 ug/day, Amgen-Roche Munchen, Germany) was commenced to increase the number of circulating hematopoietic progenitor cells during leukocyte recovery. Administration of G-CSF was continued until PBPC harvesting was completed. Measurements of circulating CD34+ cells were begun when the WBC reached a level of greater than 1.0 x 1O 9 /1. PBPC collection was initiated when a distinct population of CD34+ cells (CD34+ >20 cells/ ul) could be detected.
Collection of PBPCs and cryopreservation procedure
Harvesting was performed with a Fenwal CS 3000 (Baxter Deutschland, Munchen, Germany) or with a Cobe Spectra (Cobe, Lakewood, CO, USA) For each leukapheresis, 10-20 I blood was processed at a flow rate of 50 to 150 ml/min using large bore central venous catheters as previously described [8] The apheresis product of a 50 ml cell suspension was mixed with the same volume of minimal essential medium containing 20% dimethyl-sulfoxide (DMSO; Merck, Darmstadt, Germany).
The final suspension was stored at -196 = C as previously described [9] . The PBPC mobilization and collection was considered successful if > 2.0 x 10 6 CD34+ cells/kg BW were harvested.
Clonogenic assay for hematopoietic progenitor cells
The concentration of hematopoietic progenitor cells in each single leukapheresis product and in the peripheral blood was assessed using a semisolid clonogenic culture assay (Terry Fox Laboratories, Vancouver, Canada) as previously described [9] .
Immunofluorescence staining and flow cytometry
For immunofluorescence analysis, 20 ul of whole blood or 1 x 10 6 mononuclear cells were incubated for 30 minutes at 4°C with the fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody (moAb) HPCA-2 (anti-CD34, Becton Dickinson, Heidelberg, Germany) and analyzed using a Becton Dickinson FACScan as previously described [9] Pre-transplantation conditioning regimen and intensive care post transplantation
In 50 patients, the pre-transplantation conditioning therapy consisted of TBI (14.4 Gy, hyperfractionated over four days) and 140 mg/m 2 melphalan or in 50 patients of 200 mg/m 2 melphalan alone because of previous spinal radiotherapy, refusal of TBI or reduced pulmonary diffusion capacity Following high-dose conditioning therapy, PBPC were reinfused without additional bone marrow or growth factor support. Patients received prophylactic bowel decontamination, and antibiotic combination therapy was administered for fever >38.5°C while amphotericin-B was added in case of documented fungal infection or persistent fever. A platelet count greater than 20 x 10 9 /l was maintained by ABO-matched platelet transfusions, and packed red blood cells were given when the hemoglobin level was less than 8 g/dl.
Statistical analysis
The clinical and laboratory data from the patients were evaluated according to standard statistical methods using a commercially available computer program (Statistica for Windows, Stat Soft, Tulsa, OK, USA)
Results
PBPC collection and autografting with G-CSF-mobilized PBPC
PBPC were harvested with a median of three leukapheresis (range 1-10) resulting in 3. 1. The non-hematological toxicity is shown in Table 2 . Following TBI, more days with fever and antibiotic as well as antimycotic treatment were observed. In the TBI group, significantly longer periods of parenteral nutrition were necessary due to severe mucositis. The increased number of platelet and erythrocyte transfusions could be caused by the shorter survival of blood cells during fever. As a result of the similar hematological reconstitution in both treatment groups, the time of hospitalization was not different. Two transplantation-related deaths were observed in the TBI group (one patients with severe mucositis and sepsis with multiorgan failure at day 23, a second patient with cardiac failure 13 days post-transplantation). Figure 2 Overall and event-free survival after PBPC transplantation of 100 patients with multiple myeloma. the TBI group and 19 patients from the melphalan group, Table 3 ). Fifty-eight patients are alive in remission after a median follow-up time of 16.0 months (range 3-51), while 40 patients relapsed between 2 and 43 months post-transplantation. Ten patients died of relapsed disease, four patients of infectious complications after disease progression, one patient of CMV infection and one patient of pneumonia following allogeneic transplantation.
Follow-up post-transplantation
The EFS is 50% 22 months post-transplantation and the OS is 68% after 36 months (Figure 2) . A plateau in EFS is not reached after PBPCT. In our patient group, the main factors predicting relapse or disease progression were elevated (3 2 -microglobulin > 6.0 mg/1 (P -0.0099), stage B according to the Salmon-Durie classification (P = 0.0007) and not reaching CR or PR before transplantation (P = 0.0593).
Conclusion
In patients with multiple myeloma, high-dose therapies have been shown to improve remission rates compared to conventional treatment. The final analysis of the French multicenter trial IFM 90 showed a significantly longer EFS and OS following high-dose treatment [5] . Similar results were presented in 1995 by Barlogie et al. at the ASH meeting [10] . The data from the Royal Marsden group [11] show that HD-Mel is an outstanding active agent in the treatment of MM. With particular regard to the inclusion or omission of TBI in the highdose concept, data are only available for small patient groups. In a retrospective analysis of 85 patients, the remission state in chemosensitive patients was improved with TBI plus HD-Mel compared to HD-Mel alone [12] . In refractory patients, the toxicity of TBI-containing treatment is up to 20% [13] . No randomized study comparing TBI plus chemotherapy with HD-Mel has been carried out yet [14] .
Our results from 100 patients show no advantage of the TBI-containing high-dose therapy in reaching PR or CR over the treatment with HD-Mel alone. On the other hand, the treatment-related toxicity was significantly increased in the TBI group, in which the two toxic deaths occured. Prospective randomized studies are required to address the question of the best high-dose regimen prior to transplantation of autologous PBPC in patients with multiple myeloma.
